Clinical Trials Logo

Leptomeningeal Metastasis clinical trials

View clinical trials related to Leptomeningeal Metastasis.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06431685 Recruiting - NSCLC Clinical Trials

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Start date: April 25, 2024
Phase: Phase 1
Study type: Interventional

This phase I study aims to investigate the safety and efficacy of whole brain low dose radiotherapy (WB-LDRT) combined with ICI and intrathecal chemotherapy for treatment of refractory meningeal metastasis of lung cancer.

NCT ID: NCT06417710 Recruiting - Clinical trials for Leptomeningeal Metastasis

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis

NANO-LM
Start date: January 30, 2022
Phase:
Study type: Observational

The goal of this project is to develop and validate a reproducible scorecard for the neurological assessment of patients with leptomeningeal metastases that can be used in clinical trials including such patients, as well as in clinical practice.

NCT ID: NCT06399926 Recruiting - Lung Cancer Clinical Trials

Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir

Start date: October 30, 2023
Phase:
Study type: Observational

This is a open-label, multi-center prospective observation study for the efficacy and safety of intraventricle pemetrexed disodium via ommaya reservoir in the treatment of leptomeningeal metastasis with lung cancer who have failed at least one targeted therapy. In detail: At least the treatment failure was after third-generation EGFR-TKIs in EGFR-mutated lung cancer; or at least the treatment failure was after second-generation ALK-TKIs in ALK-mutated lung cancer; or at least the treatment failure was after one-line of targeted-TKIs in ROS1-mutated non-squamous non-small lung cancer.

NCT ID: NCT06304441 Recruiting - Clinical trials for Leptomeningeal Metastasis

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Start date: March 2024
Phase: N/A
Study type: Interventional

Intrathecal chemotherapy is one of the mainstay treatment options for leptomeningeal metastases. Pemetrexed is one of the first-line chemotherapeutic agents for non-squamous non-small cell lung cancer (NSCLC). Since 2017, intrathecal pemetrexed has shown good efficacy for patients with leptomeningeal metastases from NSCLC. It has been recommended as the preferred drug for intrathecal chemotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines. Tyrosine kinase inhibitors (TKIs) play a promising role in the treatment of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations. Due to its small molecule properties, it can effectively penetrate the central nervous system barrier and deliver an effective antitumor effect. An international multi-center clinical study published in 2019 confirmed that double-dose of osimertinib showed significant improvement in leptomeningeal metastases from NSCLC with EGFR exon 19 deletion or exon 21 L858R/T790M mutation. It makes TKIs the mainstay of treatment for patients with EGFR-mutant NSCLC with leptomeningeal metastases. However, whether third-generation small molecule TKI drugs (e.g. 'osimertinib') combined with intrathecal pemetrexed could benefit patients with LM from EGFR- mutant NSCLC remains undetermined.

NCT ID: NCT06230055 Recruiting - Clinical trials for HER2-negative Breast Cancer

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

Start date: January 5, 2024
Phase: Phase 4
Study type: Interventional

This is a prospective, multicenter, randomized controlled, open-label investigator-initiated clinical study to evaluate the clinical efficacy and quality of life of intrathecal chemotherapy through Ommaya reservoir in combination with systematic chemotherapy versus systemic chemotherapy alone in patients with Her-2 negative breast cancer with leptomeningeal metastasis.

NCT ID: NCT06058988 Recruiting - Glioblastoma Clinical Trials

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Start date: September 22, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

NCT ID: NCT05800275 Recruiting - Clinical trials for Leptomeningeal Metastasis

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

ETIC-LM
Start date: December 18, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy of tucatinib and capecitabine in combination with intrathecal trastuzumab on overall survival rate at 12 months in HER2-positive metastatic breast cancer (MBC) patients with proven leptomeningeal evolution and requiring intrathecal therapy.

NCT ID: NCT05746754 Recruiting - Clinical trials for Leptomeningeal Metastasis

Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis

CSI ProLong
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Leptomeningeal metastasis is a rare but serious complication to cancer, with a grave prognosis. No efficient treatment exists. Recent data suggest that craniospinal radiotherapy lead to superior survival and CNS control compared to focal photon radiotherapy. We want to offer Danish patients the new treatment, but within a protocol, as this is new data with an new treatment principle

NCT ID: NCT05598853 Recruiting - Melanoma Stage IV Clinical Trials

Intrathecal Double Checkpoint Inhibition

IT-IO
Start date: November 25, 2022
Phase: Phase 1
Study type: Interventional

The objective of the present study is to determine the feasibility and to explore anti-tumor activity of intrathecal double immune checkpoint inhibition for patients with newly diagnosed leptomeningeal metastases from non-small cell lung cancer without driver mutation or melanoma.

NCT ID: NCT05385185 Recruiting - Clinical trials for Leptomeningeal Metastasis

Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer

Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

immune checkpoint inhibitor combined with recombinant human endostatin can improve the 3-month OS rate of leptomeningeal metastasis of lung cancer, and the combination is safe